王涛,赵云霞,江魁

• 1:河南晟明生物技术研究院有限公司

摘要(Abstract)：

自2019年12月以来，新型冠状病毒（SARS-CoV-2）在全球范围内迅速传播，逐步发展成全球大流行疾病（COVID-19），为全球社会带来了重大损失。疫苗接种是预防传染性疾病的重要措施之一，自COVID-19流行以来，研制安全、有效的疫苗成为了当下最紧急的任务。据报道，目前全球范围内多条技术路线研究的疫苗多达172种处于临床阶段。世界卫生组织紧急批准了超过10种新冠疫苗用于紧急预防。然而，目前已获批的疫苗几乎都是针对原始毒株进行研发的。面对目前不断突变的病毒，开发更加广谱、高效的第二代新冠疫苗就显得尤为重要了。本文汇总了目前研究进展较快的第二代新冠疫苗，同时对第二代新冠疫苗的临床研究所应关注的问题及所面临的挑战进行了论述。

关键词(KeyWords)： 新型冠状病毒;临床研究;新冠疫苗

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 王涛,赵云霞,江魁

DOI: 10.13242/j.cnki.bingduxuebao.004346

参考文献(References)：

• [1] Tan W, Zhao X, Ma X, Wang W, Niu P, Xu W, Gao G F, Wu G. A novel coronavirus genome identified in a cluster of pneumonia cases-Wuhan, China 2019-2020[J]. China CDC Wkly, 2020, 2(4):61-62.
• [2] The 2019-nCoV Outbreak Joint Field Epidemiology Investigation Team, Li Q. An outbreak of NCIP(2019-nCoV)infection in China-Wuhan, Hubei province,2019-2020[J]. China CDC Wkly, 2020, 2(5):79-80.
• [3] Sanyaolu A, Marinkovic A, Prakash S, Abbasi A F,Patidar R, Williams M, Zhao A, Dzando G, Okorie C,Izurieta R. A look at COVID-19 global health situation,1-year post declaration of the pandemic[J]. Microbiol Insights, 2022, 15:11786361221089736.
• [4] WHO. Coronavirus COVID-19 Dashboard[EB/OL],onvisit 2022.11.11"https：//covid19.who.int".
• [5] Grubaugh N D, Hodcroft E B, Fauver J R, Phelan A L, Cevik M. Public health actions to control new SARSCoV-2 variants[J]. Cell, 2021, 184(5):1127-1132.
• [6] Kannan S R, Spratt A N, Cohen A R, Naqvi S H,Chand H S, Quinn T P, Lorson C L, Byrareddy S N,Singh K. Evolutionary analysis of the Delta and Delta Plus variants of the SARS-CoV-2 viruses[J]. J Autoimmun, 2021, 124:102715.
• [7] WHO News.[EB/OL], 2020.12.31"https：//www.who.int/emergencies/disease-outbreak-news/item/2020-DON305".
• [8] Tian D, Sun Y, Zhou J, Ye Q. The global epidemic of the SARS-CoV-2 Delta variant, key spike mutations and immune escape[J]. Front Immunol, 2021, 12:751778.
• [9] Zuckerman N S, Fleishon S, Bucris E, Bar-Ilan D,Linial M, Bar-Or I, Indenbaum V, Weil M, Lustig Y,Mendelson E, Mandelboim M, Mor O, Zuckerman N,On Behalf Of The Israel National Consortium For SarsCo V S. A unique SARS-CoV-2 spike protein P681H variant detected in Israel[J]. Vaccines(Basel),2021, 9(6).
• [10]Ou S, Huang Z, Lan M, Ye J, Chen J, Guo H, Xiao J, Zhuang S, Wu J, Yang C, Fang M, Su Y, Wu T,Ge S, Cheng T, Zhang Y, Lin Y, Zhang Y, Chen G,Yuan Q. The duration and breadth of antibody responses to 3-dose of inactivated COVID-19 vaccinations in healthy blood donors:an observational study[J]. Front Immunol, 2022, 13:1027924.
• [11]Cameroni E, Bowen J E, Rosen L E, Saliba C, Zepeda S K, Culap K, Pinto D, VanBlargan L A, De Marco A, di Iulio J, Zatta F, Kaiser H, Noack J, Farhat N,Czudnochowski N, Havenar-Daughton C, Sprouse K R, Dillen J R, Powell A E, Chen A, Maher C, Yin L,Sun D, Soriaga L, Bassi J, Silacci-Fregni C,Gustafsson C, Franko N M, Logue J, Iqbal N T,Mazzitelli I, Geffner J, Grifantini R, Chu H, Gori A,Riva A, Giannini O, Ceschi A, Ferrari P, CippàP E,Franzetti-Pellanda A, Garzoni C, Halfmann P J,Kawaoka Y, Hebner C, Purcell L A, Piccoli L, Pizzuto M S, Walls A C, Diamond M S, Telenti A, Virgin H W, Lanzavecchia A, Snell G, Veesler D, Corti D.Broadly neutralizing antibodies overcome SARS-CoV-2Omicron antigenic shift[J]. Nature, 2022, 602(7898):664-670.
• [12]Tartof S Y, Slezak J M, Fischer H, Hong V, Ackerson B K, Ranasinghe O N, Frankland T B, Ogun O A,Zamparo J M, Gray S, Valluri S R, Pan K, Angulo F J, Jodar L, McLaughlin J M. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA:a retrospective cohort study[J]. Lancet, 2021, 398(10309):1407-1416.
• [13]Haque A, Pant A B. Efforts at COVID-19 vaccine development:challenges and successes[J]. Vaccines(Basel), 2020, 8(4).
• [14]Gebre M S, Rauch S, Roth N, Yu J, Chandrashekar A, Mercado N B, He X, Liu J, McMahan K, Martinot A, Martinez D R, Giffin V, Hope D, Patel S, Sellers D, Sanborn O, Barrett J, Liu X, Cole A C, Pessaint L, Valentin D, Flinchbaugh Z, Yalley-Ogunro J,Muench J, Brown R, Cook A, Teow E, Andersen H,Lewis M G, Boon A C M, Baric R S, Mueller S O,Petsch B, Barouch D H. Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine[J]. Nature, 2022, 601(7893):410-414.
• [15]Liu J, Budylowski P, Samson R, Griffin B D,Babuadze G, Rathod B, Colwill K, Abioye J A,Schwartz J A, Law R, Yip L, Ahn S K, Chau S,Naghibosadat M, Arita Y, Hu Q, Yue F Y, Banerjee A, Hardy W R, Mossman K, Mubareka S, Kozak R A, Pollanen M S, Martin Orozco N, Gingras A C,Marcusson E G, Ostrowski M A. Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B[J]. Sci Adv, 2022, 8(3):eabj9815.
• [16]Stewart-Jones G B E, Elbashir S M, Wu K, Lee D,Renzi I, Ying B, Koch M, Sein C E, Choi A,Whitener B, Garcia-Dominguez D, Henry C, Woods A, Ma L, Montes Berrueta D, Avena L E, Quinones J, Falcone S, Hsiao C J, Scheaffer S M, Thackray L B, White P, Diamond M S, Edwards D K, Carfi A.Development of SARS-CoV-2 mRNA vaccines encoding spike N-terminal and receptor binding domains[Preprint]. bioRxiv, 2022, DOI:10.1101/2022.10.07.511319.
• [17]Suschak J J, Williams J A, Schmaljohn C S.Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity[J]. Hum Vaccin Immunother, 2017, 13(12):2837-2848.
• [18]Tebas P, Yang S, Boyer J D, Reuschel E L, Patel A,Christensen-Quick A, Andrade V M, Morrow M P,Kraynyak K, Agnes J, Purwar M, Sylvester A,Pawlicki J, Gillespie E, Maricic I, Zaidi F I, Kim K Y,Dia Y, Frase D, Pezzoli P, Schultheis K, Smith T R F, Ramos S J, McMullan T, Buttigieg K, Carroll M W, Ervin J, Diehl M C, Blackwood E, Mammen M P,Lee J, Dallas M J, Brown A S, Shea J E, Kim J J,Weiner D B, Broderick K E, Humeau L M. Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2:a preliminary report of an open-label,phase 1 clinical trial[J]. EClinicalMedicine, 2021, 31:100689.
• [19]Andrade V M, Christensen-Quick A, Agnes J, Tur J,Reed C, Kalia R, Marrero I, Elwood D, Schultheis K,Purwar M, Reuschel E, McMullan T, Pezzoli P,Kraynyak K, Sylvester A, Mammen M P, Tebas P,Joseph Kim J, Weiner D B, Smith T R F, Ramos S J,Humeau L M, Boyer J D, Broderick K E. INO-4800DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants[J]. NPJ Vaccines, 2021, 6(1):121.
• [20]Hsieh S M, Liu W D, Huang Y S, Lin Y J, Hsieh E F, Lian W C, Chen C, Janssen R, Shih S R, Huang C G, Tai I C, Chang S C. Safety and immunogenicity of a recombinant stabilized prefusion SARS-CoV-2 spike protein vaccine(MVC-COV1901)adjuvanted with CpG1018 and aluminum hydroxide in healthy adults:a phase1, dose-escalation study[J]. EClinicalMedicine, 2021,38:100989.
• [21]Hsieh S M, Liu M C, Chen Y H, Lee W S, Hwang S J, Cheng S H, Ko W C, Hwang K P, Wang N C, Lee Y L, Lin Y L, Shih S R, Huang C G, Liao C C, Liang J J, Chang C S, Chen C, Lien C E, Tai I C, Lin T Y.Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901:interim results of a largescale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan[J]. Lancet Respir Med, 2021, 9(12):1396-1406.
• [22]Kaabi N A, Yang Y K, Du L F, Xu K, Shao S, Liang Y, Kang Y, Su J G, Zhang J, Yang T, Hussein S,ElDein M S, Yang S S, Lei W, Gao X J, Jiang Z,Cong X, Tan Y, Wang H, Li M, Mekki H M, Zaher W, Mahmoud S, Zhang X, Qu C, Liu D Y, Zhang J,Yang M, Eltantawy I, Hou J W, Lei Z H, Xiao P,Wang Z N, Yin J L, Mao X Y, Zhang J, Qu L, Zhang Y T, Yang X M, Wu G, Li Q M. Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial[J].Nat Commun, 2022, 13(1):3654.
• [23]Alleva D G, Delpero A R, Scully M M, Murikipudi S,Ragupathy R, Greaves E K, Sathiyaseelan T, Haworth J R, Shah N J, Rao V, Nagre S, Lancaster T M,Webb S S, Jasa A I, Ronca S E, Green F M, Elyard H A, Yee J, Klein J, Karnes L, Sollie F, Zion T C.Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452[J]. Vaccine, 2021, 39(45):6601-6613.
• [24]Janssen Y F, Feitsma E A, Boersma H H, Alleva D G, Lancaster T M, Sathiyaseelan T, Murikipudi S,Delpero A R, Scully M M, Ragupathy R, Kotha S,Haworth J R, Shah N J, Rao V, Nagre S, Ronca S E,Green F M, Aminetzah A, Sollie F, Kruijff S, Brom M, van Dam G M, Zion T C. Phase I interim results of a phase I/II study of the IgG-Fc fusion COVID-19subunit vaccine, AKS-452[J]. Vaccine, 2022, 40(9):1253-1260.
• [25]Hofmeyer K A, Bianchi K M, Wolfe D N. Utilization of viral vector vaccines in preparing for future pandemics[J]. Vaccines(Basel), 2022, 10(3).
• [26]Spencer A J, Morris S, Ulaszewska M, Powers C,Kailath R, Bissett C, Truby A, Thakur N, Newman J,Allen E R, Rudiansyah I, Liu C, Dejnirattisai W,Mongkolsapaya J, Davies H, Donnellan F R, Pulido D, Peacock T P, Barclay W S, Bright H, Ren K,Screaton G, McTamney P, Bailey D, Gilbert S C,Lambe T. The ChAdOx1 vectored vaccine, AZD2816,induces strong immunogenicity against SARS-CoV-2beta(B. 1.351)and other variants of concern in preclinical studies[J]. EBioMedicine, 2022, 77:103902.
• [27]van Doremalen N, Schulz J E, Adney D R, Saturday T A, Fischer R J, Yinda C K, Thakur N, Newman J,Ulaszewska M, Belij-Rammerstorfer S, Saturday G,Spencer A J, Bailey D, Russell C A, Gilbert S C,Lambe T, Munster V J. ChAdOx1 nCoV-19(AZD1222)or nCoV-19-Beta(AZD2816)protect syrian hamsters against Beta Delta and Omicron variants[J]. Nat Commun, 2022, 13(1):4610.
• [28]Sieling P, Zakin L, Shin A, Morimoto B, Adisetiyo H,Garban H, Liu P, Rice A, Taft J, Patel R, Buta S,Martin-Fernandez M, Bogunovic D, Gabitzsch E, Safrit J T, Sender L, Spilman P, Rabizadeh S, Niazi K, Soon-Shiong P. Th1 dominant nucleocapsid and spike antigenspecific CD4+and CD8+memory T cell recall induced by hAd5 S-fusion+N-ETSD infection of autologous dendritic cells from patients previously infected with SARS-CoV-2[Preprint]. medRxiv, 2020, DOI:10.1101/2020.11.04.20225417.
• [29]Guirakhoo F, Kuo L, Peng J, Huang J-H, Kuo B-S,Lin F, Liu Y-J, Liu Z, Wu G, Ding S, Hou K-L,Cheng J, Yang V, Jiang H, Wang J, Chen T, Xia W,Lin E, Hung C H, Chen H-J, Shih Z, Lin Y-L, Wang S, Ryan V, Schurter B T, Hu M M, Heppner G,Malherbe D C, Bukreyev A, Hellerstein M, Monath T P, Wang C Y. A novel SARS-CoV-2 multitope protein/peptide vaccine candidate is highly immunogenic and prevents lung infection in an AAV hACE2 mouse model and non-human primates[Preprint]. bioRxiv, 2021,DOI:10.1101/2020.11.30.399154.
• [30]Wang S, Wang C Y, Kuo H K, Peng W J, Huang J H,Kuo B S, Lin F, Liu Y J, Liu Z, Wu H T, Ding S,Hou K L, Cheng J, Yang Y T, Jiang M H, Wang M S, Chen T, Xia W G, Lin E, Hung C H, Chen H J,Shih Z, Lin Y L, Ryan V, Hu M M, Heppner D G,Malherbe D C, Periasamy S, Kuzmina N, Subramani C, Hellerstein M, Monath T P, Rumyantsev A,Bukreyev A, Guirakhoo F. A novel RBD-protein/peptide vaccine elicits broadly neutralizing antibodies and protects mice and macaques against SARS-CoV-2[J].Emerg Microbes Infect, 2022, 11(1):2724-2734.
• [31]Guirakhoo F, Wang S, Wang C Y, Kuo H K, Peng W J, Liu H, Wang L, Johnson M, Hunt A, Hu M M,Monath T P, Rumyantsev A, Goldblatt D. High neutralizing antibody levels against severe acute respiratory syndrome coronavirus 2 Omicron BA. 1 and BA. 2 after UB-612 vaccine booster[J]. J Infect Dis,2022, 226(8):1401-1406.
• [32]Gauttier V, Morello A, Girault I, Mary C, Belarif L,Desselle A, Wilhelm E, Bourquard T, Pengam S,Teppaz G, Thepenier V, Biteau K, De Barbeyrac E,KiepferléD, Vasseur B, Le Flem F, Debieuvre D,Costantini D, Poirier N. Tissue-resident memory CD8 T-cell responses elicited by a single injection of a multitarget COVID-19 vaccine[Preprint]. bioRxiv, 2020,DOI:10.1101/2020.08.14.240093.
• [33]Evans J P, Qu P, Zeng C, Zheng Y M, Carlin C,Bednash J S, Lozanski G, Mallampalli R K, Saif L J,Oltz E M, Mohler P J, Gumina R J, Liu S L.Neutralization of the SARS-CoV-2 Deltacron and BA.3variants[J]. N Engl J Med, 2022, 386(24):2340-2342.
• [34]AboulFotouh K, Cui Z, Williams R O, 3rd. Nextgeneration COVID-19 vaccines should take efficiency of distribution into consideration[J]. AAPS PharmSciTech, 2021, 22(3):126.
• [35]Burnett D L, Jackson K J L, Langley D B, Aggrawal A, Stella A O, Johansen M D, Balachandran H,Lenthall H, Rouet R, Walker G, Saunders B M, Singh M, Li H, Henry J Y, Jackson J, Stewart A G,Witthauer F, Spence M A, Hansbro N G, Jackson C,Schofield P, Milthorpe C, Martinello M, Schulz S R,Roth E, Kelleher A, Emery S, Britton W J, Rawlinson W D, Karl R, Sch?fer S, Winkler T H, Brink R, Bull R A, Hansbro P M, J?ck H M, Turville S, Christ D,Goodnow C C. Immunizations with diverse sarbecovirus receptor-binding domains elicit SARS-CoV-2neutralizing antibodies against a conserved site of vulnerability[J]. Immunity, 2021, 54(12):2908-2921.e2906.
• [36]Williams T C, Burgers W A. SARS-CoV-2 evolution and vaccines:cause for concern?[J]. Lancet Respir Med, 2021, 9(4):333-335.
• [37]Steuwer B, Jamrozik E, Eyal N. Prioritizing secondgeneration SARS-CoV-2 vaccines through low-dosage challenge studies[J]. Int J Infect Dis, 2021, 105:307-311.